Uterine Cancer Drugs Market Perspective by Comprehensive Analysis Growth Prediction to 2026

Uterine-Cancer-Drugs-Market

Increasing funding for cancer research, rising insurance coverage, and increasing number of new targeted cancer drugs are supporting the revenue growth of uterine cancer drugs market size. For instance, National Cancer Institute, in 2015, invested around US$ 4,480 million on cancer research, which include uterine cancer, cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, and ovarian cancer. Furthermore, according to the American Cancer Society, U.S. has spent around US$ 87.8 billion in 2014, on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.

Chemotherapy is the most recommended therapy suggested for treatment of uterine sarcomas. However, chemotherapy may not work in certain types of uterine sarcoma. Chemotherapy for uterine sarcoma is often conducted in the earlier stages of cancer. Various chemotherapy drugs used in the treatment of uterine sarcoma include Paclitaxel (Taxol), Docetaxel (Taxotere), Dacarbazine (DTIC), Liposomal doxorubicin (Doxil), Epirubicin (Ellence), and among others.

Furthermore, increasing number of clinical trials conducted for treatment of endometrial cancer and uterine sarcoma are expected to augment growth of the uterine cancer drugs market. According to U.S. National Library of Medicine, August 2017, clinical trials database, Memorial Sloan Kettering Cancer Center: a cancer treatment and research institute in New York, is engaged in conducting two clinical trial studies for uterine cancer, which includes Phase II study of Nivolumab immunotherapy to treat recurrent or persistent uterine cancer and second is the Selinexor (KPT-330) with Paclitaxel and Carboplatin, present in phase I clinical stage for treating advanced ovarian and endometrial cancers.

To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/1745

Uterine cancer is one of the most common gynecologic malignancy among female cancer patients. This uterine cancer is of two types: endometrial cancer and uterine sarcoma. Endometrial cancer is caused due to uncontrolled growth of inner linings of uterus. Endometrial cancer is often curable, however, uterine sarcoma is rare cancer, which develops in the muscle and supporting tissues of the uterus (womb). According to National Cancer Institute, Megestrol Acetate is only drug approved by U.S. Food and Drug Administration (FDA) for the treatment of endometrial cancer till March 2016. Diagnosis of both types of uterine cancer is done through endometrial biopsy, colposcopy or Pap smear screening test.

You may be interested

Refurbished Medical Equipment Market Positive long-term growth outlook 2018-2026
Healthcare
Healthcare

Refurbished Medical Equipment Market Positive long-term growth outlook 2018-2026

Albert R - August 19, 2018

Refurbished Medical Equipment Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…

Stem Cell Assay Market Trends Estimates High Demand by 2026
Healthcare
Healthcare

Stem Cell Assay Market Trends Estimates High Demand by 2026

Albert R - August 19, 2018

Stem Cell Assay Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…

Urolithiasis Management Devices Market to Grow Like Never Before By 2026
Healthcare
Healthcare

Urolithiasis Management Devices Market to Grow Like Never Before By 2026

Albert R - August 19, 2018

Urolithiasis Management Devices Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…

Most from this category